Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

RubrYc Therapeutics

  • Isaac Bright, RubrYc Therapeutics, Inc.

RubrYc Therapeutics is a discovery-stage therapeutic antibody business focused on addressing unmet needs in Oncology and Autoimmune Diseases. The Company was founded in 2017 and launched in April, 2018 with a $10M Series A Preferred financing. RubrYc has developed the Interface Discovery Engine – the operating system the Company employs, leveraging machine learning to realize critical efficiency gains in drug discovery. Team RubrYc maintains intense focus on advancing its proprietary pipeline programs, while engaging in target-specific Platform Partnerships with industry incumbents. The Company will complete platform feasibility, demonstrate non-GLP PoC with its molecules, and raise Series B in 2019.

  • Date:Monday, February 11
  • Time:3:45 PM - 4:00 PM
  • Room:Gramercy
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance at:http://bit.ly/BIOCEO19question
  • Submission ID:23297
  • Company Presentation - Presentation Type:Privately Funded Company
  • Goal for Presentation:Initiate Investor Discussions for Series B Preferred financing
  • Company Website:www.rubryc.com
  • Company HQ City:San Ramon
  • Company HQ State:California
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$10M
  • Size of Last Investment Round:$10M
  • Previous and Current Investors:Third Point, Paladin, Vital
  • CEO/Top Company Official:Isaac Bright
  • Year Founded:2017
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:RTX-001
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):3
Speakers
Isaac Bright
RubrYc Therapeutics, Inc.
Back